Clinical Trials Logo

Pancreatectomy; Hyperglycemia clinical trials

View clinical trials related to Pancreatectomy; Hyperglycemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05177653 Completed - Clinical trials for Pancreatectomy; Hyperglycemia

Separate and Combined Extrapancreatic Effects of the Incretin Hormones

GA-19
Start date: April 7, 2022
Phase: N/A
Study type: Interventional

The two gut-derived hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) is secreted from intestinal cells in relation to a meal and increase insulin secretion from the pancreas. The hormones also exert effects outside the pancreas, but especially for GIP, these are poorly investigated. Because of this, only GLP-1 based drugs (GLP-1 receptor agonists) are on the market for the treatment of type 2 diabetes and obesity. Nonetheless, a new drug is in clinical development: a combined GIP-GLP-1-receptor agonist (tirzepatide), which has shown better results than GLP-1 alone. The mechanism behind these impressive effects are unknown and in this study, the investigators will look into the exptrapancreatic effects of GIP and GLP-1, separate and combined and thus elucidate the mechanisms of action of this new drug class.

NCT ID: NCT04409171 Completed - Diabete Mellitus Clinical Trials

Glucose Metabolism After Partial Pancreatectomy

Start date: September 1, 2015
Phase:
Study type: Observational [Patient Registry]

This is a single center observational study to assess alteration of glucose metabolism after pancreatectomy.

NCT ID: NCT03303196 Completed - Diabetes Clinical Trials

Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes

Start date: April 9, 2018
Phase: N/A
Study type: Interventional

This is a pilot study designed to determine if the bihormonal bionic pancreas provides improved blood glucose control, compared to the current standard of care, in individuals with hyperinsulinism who developed diabetes after having a pancreatectomy.

NCT ID: NCT03174353 Completed - Pancreatic Fistula Clinical Trials

A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

This is a single arm investigator-initiated study designed to test the feasibility and potential efficacy of preoperative lanreotide to reduce the risk of postoperative abscess or pancreatic leak and fistula. All consenting patients undergoing planned elective pancreaticoduodenectomy or distal pancreatectomy for malignancy or suspected malignancy will be treated with a single deep subcutaneous dose of lanreotide prior to planned resection on the day of surgery. Following this intervention, care will be based on standard treatment protocols. Sixty-day mortality and morbidity will be collected for all patients.